Ultrasound-guided meniscal wall injection for knee osteoarthritis treatment
Evaluation of the Performance of Six-month Wall Infiltration Under Ultrasound to Treat Stable Degenerative Meniscal Injuries. A Single-center, Randomized, Double-blind Study.
This study is testing whether a new way of injecting corticosteroids directly into the meniscus can help people with knee osteoarthritis feel better compared to the usual injection method.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 1 site (Nimes) |
| Trial ID | NCT05235854 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of ultrasound-guided infiltration of corticosteroids into the meniscal wall for treating stable degenerative meniscal injuries compared to traditional intra-articular injections. The primary goal is to determine if this targeted approach provides greater relief, as measured by the Lysholm score, at three months post-treatment. Patients with symptomatic meniscal lesions will be recruited, and their outcomes will be compared to those receiving standard treatment. The study aims to provide insights into a potentially more effective treatment for knee osteoarthritis-related meniscal injuries.
Who should consider this trial
Good fit: Ideal candidates are adults with symptomatic degenerative meniscal lesions confirmed by imaging, who are stable and have early-stage osteoarthritis.
Not a fit: Patients with advanced osteoarthritis or other significant knee injuries may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this approach could offer patients improved pain relief and functional outcomes for knee osteoarthritis.
How similar studies have performed: While similar approaches have been explored, this specific method of meniscal wall infiltration under ultrasound is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a symptomatic meniscal lesion of a degenerative nature, isolated or associated with early osteoarthritis or chondropathy (Ahlbach stages 1 and 2). * Indication for peri-meniscal infiltration under ultrasound control of the knee for a clinically stable degenerative meniscal lesion confirmed by MRI and radiography. * Patient who has given free and informed consent. * Patient who has signed the consent form. * Patient affiliated or beneficiary of a health insurance plan. * Adult patient (≥18 years of age). Exclusion Criteria: * No iconographic evidence of meniscal injury. * Associated lesions of the central pivot of the knee. * Knee pain of osteoarthritic origin strongly suggested by the clinic associated with an advanced radiological stage of osteoarthritis (Ahlbach stages 3 and 4). * Presence of a skin lesion at the infiltration sites. * Suspected soft tissue or joint infection. * Patient participating in research involving human subjects defined as Category 1. * Patient in an exclusion period as determined by another study. * Patient under court protection, guardianship or trusteeship. * Patient unable to give consent. * Patient for whom it is impossible to give informed information. * Pregnant, parturient or breastfeeding women.
Where this trial is running
Nimes
- Chu Nimes — Nimes, France (Recruiting)
Study contacts
- Study coordinator: Philippe MARCHAND, Dr.
- Email: philippe.marchand@chu-nimes.fr
- Phone: +33 4.66.68.72.93
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.